Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Rating) has received a consensus rating of “Hold” from the nine analysts that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $10.13.
A number of equities analysts recently weighed in on KPTI shares. StockNews.com cut Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, November 7th. Robert W. Baird cut their price objective on Karyopharm Therapeutics from $17.00 to $14.00 and set an “outperform” rating for the company in a research note on Friday, August 5th. SVB Leerink upped their price objective on Karyopharm Therapeutics from $5.00 to $6.00 and gave the company a “market perform” rating in a report on Friday, November 4th. Royal Bank of Canada upgraded Karyopharm Therapeutics from a “sector perform” rating to an “outperform” rating and upped their price target for the stock from $7.00 to $10.00 in a research note on Friday, November 4th. Finally, Barclays reduced their price objective on Karyopharm Therapeutics from $14.00 to $8.00 and set an “overweight” rating on the stock in a research note on Friday, August 5th.
Hedge Funds Weigh In On Karyopharm Therapeutics
Several hedge funds have recently made changes to their positions in KPTI. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Karyopharm Therapeutics by 78.0% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,641 shares of the company’s stock worth $78,000 after purchasing an additional 4,664 shares during the last quarter. Victory Capital Management Inc. purchased a new position in shares of Karyopharm Therapeutics during the first quarter worth about $1,456,000. ClariVest Asset Management LLC purchased a new position in shares of Karyopharm Therapeutics during the first quarter worth about $440,000. New York State Common Retirement Fund grew its holdings in shares of Karyopharm Therapeutics by 23.1% during the first quarter. New York State Common Retirement Fund now owns 52,425 shares of the company’s stock worth $386,000 after buying an additional 9,831 shares during the last quarter. Finally, Rice Hall James & Associates LLC grew its holdings in shares of Karyopharm Therapeutics by 5.3% during the first quarter. Rice Hall James & Associates LLC now owns 1,344,929 shares of the company’s stock worth $9,912,000 after buying an additional 68,295 shares during the last quarter. Hedge funds and other institutional investors own 84.66% of the company’s stock.
Karyopharm Therapeutics Trading Down 1.4 %
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1.
- Get a free copy of the StockNews.com research report on Karyopharm Therapeutics (KPTI)
- MarketBeat: Week in Review 11/7 – 11/11
- Oil Is a Compelling Reason The Sell-Off In Stocks Isn’t Over
- Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
- Six Flags is a Ride You Don’t Want to Get Stuck On
- Vision Hydrogen, Now Vision Energy, Puts Hopes In Stock Split
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.